Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Gentronix
Gentronix
Activities:
Manufacturing
Research & Development
X
LinkedIn
Trending Articles
Wacker Biotech to manufacture protein ingredients for MinervaX's late-stage GBS vaccine
The vaccine is currently being prepared for Phase III trials, and aims to protect mothers and their babies from group B streptococcus infections
Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer
The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
AstraZeneca opens a 'people hub' at its Macclesfield site
The energy-efficient building will offer AZ employees a collaborative space
Ensuring cGMP compliance in cell and gene therapy manufacturing
3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
Piramal Pharma's sustainability goals get SBTi-validated
The company wants to reduce its scope 1 and 2 GHG emissions by 42% by 2030, and is also working on developing a carbon reduction plan
Upcoming event
Boston Biotech Week
23-26 September, 2024 | Convention and exhibition | Boston, US
See all
Related Content
Research & Development
Scantox Group acquires genetic toxicology specialist, Gentronix
The strategic acquisition will boost the conglomerate's range of screening and regulatory genotoxicity assays and surveys
Manufacturing
Gentronix's transgenic rodent mutation workflow accommodated with new lab
This continued growth follows a successful 2300 sqft expansion in 2021 to increase capacity of genetic, ocular, and skin toxicology testing in 2021
Finance
Gentronix adds capacity and services through laboratory expansion
The business has added a further 2,300 sqft to its footprint at Alderley Park in Cheshire
Finance
Gentronix expands dermal toxicology services
The addition of phototoxicity services, planned for Q2 2021, will enable the assessment of whether materials have adverse toxicity profiles after UV light activation
Regulatory
Gentronix expands sales teams in US and Europe
Appoints Dorothy Zelent and Simon Johns
Manufacturing
Gentronix signs genotoxicity assays agreement with GSK
Gentronix to provide GreenScreen HC and BlueScreen HC genotoxicity assays to GlaxoSmithKline (GSK).
Subscribe now